mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market to Grow with a CAGR of 7.11% through 2028
Growing investment in research and development and expanding
therapeutic applications are factors driving the global mRNA Therapeutics
Contract Development & Manufacturing (CDMO) market in the forecast
period 2024-2028.
According to TechSci Research report, “mRNA
Therapeutics Contract Development & Manufacturing (CDMO) Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global mRNA Therapeutics Contract Development & Manufacturing (CDMO)
Market stood at USD 8.51 Billion in 2022 and is anticipated to grow with a CAGR
of 7.11% in the forecast period, 2024-2028. The global mRNA
therapeutics contract development and manufacturing (CDMO) market has witnessed
unprecedented growth in recent years, driven by a convergence of factors that
highlight the immense potential of messenger RNA (mRNA) technology in the field
of healthcare. mRNA therapeutics offer a novel approach to treat a wide range
of diseases, from infectious diseases and cancer to rare genetic disorders. As
the demand for mRNA-based therapies continues to rise, the CDMO sector has
become increasingly vital in accelerating the development and manufacturing of
these innovative drugs. One of the primary drivers of the mRNA therapeutics
CDMO market is the rapid advancement in mRNA technology. Scientists and
researchers have made significant progress in understanding the biology of mRNA
and optimizing its therapeutic potential. This has led to the development of
highly effective and safe mRNA-based therapies, such as the Pfizer-BioNTech and
Moderna COVID-19 vaccines, which demonstrated the real-world potential of mRNA
technology. As more diseases are targeted with mRNA therapeutics, the demand
for CDMO services to manufacture these complex products is set to surge. The biotechnology and
pharmaceutical industries have witnessed a surge in investments directed
towards mRNA-based therapies. Pharmaceutical giants, as well as startups, have
recognized the potential of mRNA in treating previously untreatable diseases.
These investments are driving the need for specialized CDMO services that can
handle the complex and delicate nature of mRNA drug development and production.
The continuous influx of funds into research and development of mRNA
therapeutics is a key market driver for CDMO companies.
mRNA technology has the potential to
address a wide range of therapeutic applications, including infectious
diseases, cancer immunotherapy, and genetic disorders. As the pipeline of
mRNA-based drugs grows, so does the demand for CDMO services. The versatility
of mRNA platforms allows for the development of customized therapies, leading
to a broader spectrum of applications and an increase in outsourcing to CDMO
providers. Regulatory bodies like the U.S. Food and
Drug Administration (FDA) have shown willingness to support and fast-track mRNA
therapeutics, especially in response to urgent public health needs. The
expedited approvals and regulatory flexibility have encouraged pharmaceutical
companies to invest in mRNA technologies, leading to an increased demand for
CDMO services. This regulatory support reduces the time-to-market for mRNA
therapies, making them more appealing to both developers and investors.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market.”
The Global mRNA Therapeutics Contract Development
& Manufacturing (CDMO) Market is segmented into application, indication end
user and company. Based on indication, the Infectious Diseases segment has
emerged as the predominant market leader. Infectious diseases continue to pose significant
global health challenges. There is an ongoing need for innovative and effective
treatments for infectious diseases, including those that have developed
resistance to existing therapies. mRNA therapeutics offer a versatile platform
that can be rapidly tailored to target emerging infectious agents.
Based on region, North America segment is expected to
grow during the forecast period. North America is home to some of
the most prominent pharmaceutical and biotech companies globally, which have
actively invested in mRNA therapeutics. Companies like Moderna, Pfizer, and
BioNTech, all based in North America, have played pivotal roles in developing
mRNA-based vaccines and therapies. Their success has not only bolstered North
America's reputation but also attracted significant attention and investment. These
established industry players have also expanded their capabilities in-house and
through collaborations with CDMOs, fueling the growth of the mRNA therapeutics
CDMO market in the region. The Asia Pacific region is experiencing rapid market
growth. The robust growth of the region’s mRNA therapeutics CDMO market has
attracted substantial investments from both domestic and international sources.
Venture capitalists, private equity firms, and strategic investors are pouring
capital into North American mRNA-focused companies and CDMOs. This influx of
funds has further accelerated research, development, and manufacturing capacity
expansion.
Major companies operating in Global mRNA
Therapeutics Contract Development & Manufacturing (CDMO) Market are:
- Danaher
corporation (Aldevron)
- Recipharm
AB
- Biomay
AG
- Samsung
Biologics
- Lonza
Group AG
- Catalent
, Inc
- Bio-Indication Inc
- Kaneka Eurogentec S.A
- TriLink
BioTechnologies
- BioNTech
SE
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global mRNA Therapeutics CDMO Market is poised
for significant growth in the coming years. As research and development efforts
continue to yield promising results, and regulatory agencies become more
familiar with mRNA-based therapies, the market is expected to expand even
further. The advent of mRNA therapies has ushered in a new era of medicine,
offering hope for patients suffering from a wide array of diseases that were
once considered untreatable.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“mRNA Therapeutics Contract Development &
Manufacturing (CDMO) Market By Application (Viral
Vaccines, Protein Replacement Therapies, Cancer Immunotherapies), By Indication
( Infectious Diseases, Metabolic & Genetic Diseases, Cardiovascular &
Cerebrovascular Diseases), By End user (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global mRNA Therapeutics Contract Development
& Manufacturing (CDMO) Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global mRNA
Therapeutics Contract Development & Manufacturing (CDMO) Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com